Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
R. De Caterina (IT), S.D. Kristensen (DK)
G. Agnelli (IT), P. Amarenco (FR), J.P. Collet (FR), E. Grove (DK), K. Huber (AT), S.E. Husted (DK), D.J. Moliterno (US), J. Morais (PT), F.J. Neumann (DE), H. Schühlen (DE), R. Storey (UK), F.W.A. Verheugt (NL), M. Zimarino (IT)
SESSION 1: PATHOPHYSIOLOGY AND METHODOLOGY Chairpersons: R. De Caterina and S.D. Kristensen 14:00-14:20 Atherothrombosis and arterial thromboembolism: update on pathophysiological background – R. De Caterina 14:20-14:40 Platelets - monitoring and ‘resistance’ to antiplatelet agents – S.D. Kristensen 14:40-14:50 Overall Discussion SESSION 2: UPDATE IN ORAL PLATELET INHIBITORS Chairpersons: S. Husted and F.W.A. Verheugt 14:50-15:10 Low-dose aspirin, coxibs, non-steroidal anti-inflammatory drugs, and the need for proton pump inhibitors – R. Storey Debate: oral P2Y12 inhibitors: what should we use? 15:10-15:20 Clopidogrel – E. Grove 15:20-15:30 Prasugrel – J-P. Collet 15:30-15:40 Ticagrelor – R. Storey 15:40-16:00 Discussion 16:00-16:15 New antiplatelet drugs: cangrelor, elinogrel, thrombin receptor antagonists and other newcomers – D.J. Moliterno 16:15-16:30 Overall Discussion
16:30-17:00 Coffee Break
SESSION 3: Case Presentations - Difficult scenarios in anti-thrombotic therapy (15 min presentations + 15 min discussion for each case) Chairpersons: E. Grove and M. Zimarino 17:00-17:30: Case 1: Stroke and recurrent left atrial appendage thrombus in a patient with atrial fibrillation under old and new oral anticoagulants – M. Rohla
17:30-18:00: Case 2 : Risk-Adjusted Strategies in Patients with Acute Pulmonary Embolism - M. Lankeit
18:00-18:30: Case 3: A case for an individualized antiplatelet regimen to prevent stent thrombosis – P. Capranzano
Chairperson: D.J. Moliterno9:00-9:20 Bivalirudin vs heparins during percutaneous interventions in acute coronary syndromes – D.J. Moliterno 9:20-9:40 GP IIb/IIIa antagonists: still needed? – S.D. Kristensen 9:40-10:00 Coronary interventions 2014: New generation of stents and intracoronary drug delivery – J.-P. Collet 10:00-10:20 Stent thrombosis with bare metal and drug-eluting stents and biovascular scaffolding devices - F.J. Neumann 10:20-10:30 – Overall Discussion
10:30-11:00 Coffee break
SESSION 4: STABLE CORONARY HEART DISEASE Chairpersons: R. Storey and K. Huber Debate: PCI for stable CHD patients 11:00-11:15 PCI for stable patients is not needed – F.W.A. Verheugt 11:15-11:30 PCI for stable patients is still needed – H. Schühlen 11:30-11.45 Chronic anti-thrombotic therapy for a chronic disease: is aspirin still needed – F.W.A. Verheugt 11:45-12:00 Complete versus incomplete revascularization – M. Zimarino 12:00-12:10 Overall Discussion The mission of the ESC: "To reduce the burden of cardiovascular disease in Europe."
SESSION 5: NON-ST ELEVATION ACUTE CORONARY SYNDROMES Chairs: R. Storey and H. Schühlen 12:10-12:25 Markers for risk stratification: why and what? – S. Husted 12:25-12:40 Preventing bleeding to prevent ischemia and death – J. Morais 12:40-12:55 Optimal timing for PCI – H. Schühlen 12:55-13:10 Discussion
SESSION 6: ACUTE ST-ELEVATION MYOCARDIAL INFARCTION Chairperson: R. De Caterina and F.J. Neumann14:00-14:15 Pre-hospital thrombolysis: why to keep it as an option in organizational models – K. Huber14:15-14:30 Combining different treatment option for cath lab therapy in STEMI – F.J. Neumann14:30-15:00 Dialogue: Primary PCI – tips and tricks - 4 key debate questions – H. Schühlen and S.D. Kristensen 15:00-15:15 New oral anticoagulants in acute coronary syndromes – R. De Caterina 15:15-15:45 Overall Discussion 15:45-16:00 Coffee BreakSession 7: Venous thromboembolism: new drugs and duration of anticoagulant therapy Chairpersons: J. Morais and F.W.A. Verheugt 16:00-16:15 Aspirin and traditional anticoagulation in venous thromboembolism. G. Agnelli 16:15-16:30 Dabigatran etexilate, rivaroxaban, apixaban, edoxaban: compared pharmacology - S. Husted 16:30 -17:00 The new anticoagulants in venous thromboembolism: new trials and duration of therapy. G. Agnelli
SESSION 8: ATRIAL FIBRILLATION Chairpersons: D.J. Moliterno and S. Husted 09:00-09:20 Risk assessment: use of warfarin, aspirin and clopidogrel - J. Morais 09:20-09:40 New anticoagulants in atrial fibrillation: comparative clinical results – R. De Caterina 0940:10:00 Which anticoagulant for which atrial fibrillation patient? P. Amarenco 10:00-10:30: Round table and overall discussion
10:30-11:00 Coffee Break
SESSION 9: MISCELLANEOUS Chairpersons: K. Huber and J. P. Collet 11:00-11:30: Secondary prevention of ischemic and hemorrhagic stroke in atrial fibrillation – P. Amarenco 11:30-11:50 Triple anti-thrombotic therapy with aspirin, P2Y12 inhibitors and vitamin K antagonists/new anticoagulants: rationale and risk – K. Huber 11:50-12:00 Concluding remarks – S.D. Kristensen and R. De Caterina
This educational course has been supported by AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb and Daiichi-Sankyo Lilly, in the form of unrestricted educational grants.The scientific programme has not been influenced in any way by its sponsors.
European Society of Cardiology
European Heart HouseLes Templiers2035 Route des CollesCS 80179 BIOT
06903 Sophia Antipolis, FR
© 2017 European Society of Cardiology. All rights reserved